Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, HIV/AIDS drug development and treatment, and COVID-19 Clinical Research Studies.
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
Regulation of CD45 isoforms during human effector and memory CD8 T cell differentiation: Implications for T cell nomenclature
The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults
Homologous and Heterologous Covid-19 Booster Vaccinations
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans
The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)